Balancing risks and therapeutic benefits. About adjuvant tamoxifen treatment for breast cancer patients

被引:7
|
作者
Sarradon-Eck, Aline [1 ]
Pellegrini, Isabelle [2 ]
机构
[1] MMSH, Ctr Norbert Elias, Equipe GReCSS PAS Anthropol Sante, F-130949 Aix En Provence, France
[2] Inst Paoli Calmette, INSERM, UMR SE4S 912, F-13273 Marseille 09, France
来源
SCIENCES SOCIALES ET SANTE | 2012年 / 30卷 / 01期
关键词
TREATMENT DECISION-MAKING; MEDICAL UNCERTAINTY; WOMENS PERCEPTIONS; CHEMOTHERAPY; HEALTH; EXPERIENCE;
D O I
10.3917/sss.301.0047
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
One of the main tools available for making bio-medical decisions about the best treatment to prescribe is the risk-benefit ratio. This article takes a contextual approach to the decision-making processes involved in the prescription of adjuvant tamoxifen as a mean of reducing the risk of relapse of breast cancer. Using anthropological descriptive methods, it examines the discrepancy between patients' and doctors' perceptions of the risks and benefits of the treatment and analyses their underlying logics. Representations of women are related to cancer (fear of the disease), its treatment (efficacy) and tamoxifen (fear of hormones and aging), and can lead to a symbolic hierarchy of treatments, whereas doctors' professional practices focus mainly on the prevention of the recurrence of cancers.
引用
收藏
页码:47 / 71
页数:25
相关论文
共 50 条
  • [41] Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer
    Sun, Zhuoxin
    Goldhirsch, Aron
    Price, Karen N.
    Colleoni, Marco
    Ravaioli, Alberto
    Simoncini, Edda
    Campbelli, Ian
    Gelber, Richard D.
    Towler, Mark
    BREAST, 2009, 18 (02) : 84 - 88
  • [42] Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns
    Abdel-Rahman, Omar
    ElHalawani, Hesham
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (11) : 1443 - 1467
  • [43] Elderly Postmenopausal Patients With Breast Cancer Are at Increased Risk for Distant Recurrence: A Tamoxifen Exemestane Adjuvant Multinational Study Analysis
    van de Water, Willemien
    Seynaeve, Caroline
    Bastiaannet, Esther
    Markopoulos, Christos
    Jones, Steve E.
    Rea, Daniel
    Hasenburg, Annette
    Putter, Hein
    Hille, Elysee T. M.
    Paridaens, Robert
    de Craen, Anton J. M.
    Westendorp, Rudi G. J.
    van de Velde, Cornelis J. H.
    Liefers, Gerrit-Jan
    ONCOLOGIST, 2013, 18 (01) : 8 - 13
  • [44] Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Ozdemir, Nuriye Y.
    Zengin, Nurullah
    Yazici, Ozan
    Sever, Ali R.
    Altundag, Kadri
    JOURNAL OF BUON, 2016, 21 (01): : 27 - 34
  • [45] A Systematic Assessment of Benefits and Risks to Guide Breast Cancer Screening Decisions
    Pace, Lydia E.
    Keating, Nancy L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (13): : 1327 - 1335
  • [46] Cardiac risks in multimodal breast cancer treatment
    Budach, Wilfried
    STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 : 9 - 10
  • [47] Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients
    Ko, Kyung Lan
    Shin, In Suk
    You, Ji Young
    Jung, So-Youn
    Ro, Jungsil
    Lee, Eun Sook
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 142 (03) : 559 - 567
  • [48] Adjuvant therapy for breast cancer patients: treatment decision tree from a French cancer network
    Bachelot, T
    Ray-Coquard, I
    Coeffic, D
    Barletta, H
    Gouttebel, MC
    Mayer, B
    Muron, T
    de Laroche, G
    Vincent, M
    Farsi, F
    Philip, T
    BULLETIN DU CANCER, 2002, 89 (10) : 897 - 903
  • [49] Adjuvant breast cancer treatment with hormono-radiotherapy
    Azria, D.
    Jacot, W.
    Gligorov, J.
    Belkacemi, Y.
    Zaman, K.
    Romieu, G.
    Ozsahin, M.
    BULLETIN DU CANCER, 2009, 96 (03) : 285 - 289
  • [50] Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015
    Zardavas, Dimitrios
    Fouad, Tamer M.
    Piccart, Martine
    BREAST, 2015, 24 : S143 - S148